Literature DB >> 9061807

Developmental trajectory and disease progression in schizophrenia: the conundrum, and insights from a 12-year prospective study in the Monaghan 101.

J L Waddington1, P J Scully, H A Youssef.   

Abstract

Though conceptualised originally as a deteriorating disorder, some contemporary studies have been interpreted as challenging these foundations; more radically, it has been proposed that schizophrenia may be a 'static encephalopathy' of neurodevelopmental origin. The argument offered here is that schizophrenia is indeed a neurodevelopmental disorder, but that this is not in itself antithetical to later disease progression. Rather, the onset of psychosis may reflect the maturationally-mediated triggering of an active disease process that is associated with progressive deterioration unless attenuated by antipsychotic drugs. A developmental trajectory is proposed to link first or early second trimester dysplasia to the chronic course of the illness; from this, it is argued that schizophrenia is inherently a progressive disorder but that antipsychotic drugs may act to ameliorate this progressive component and thus confer on the disease course some of the characteristics of a 'static encephalopathy'. The 'true' natural history of an illness cannot be determined from studies in treated populations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9061807     DOI: 10.1016/S0920-9964(96)00111-9

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  9 in total

Review 1.  Rationale for the study of early intervention.

Authors:  R J Wyatt; I Henter
Journal:  Schizophr Res       Date:  2001-08-01       Impact factor: 4.939

Review 2.  Sex or body size? Selection of dialysis type revisited.

Authors:  A Levin
Journal:  CMAJ       Date:  1999-03-23       Impact factor: 8.262

3.  Improving outcomes for patients with schizophrenia: new hope for an old illness.

Authors:  M V Seeman
Journal:  CMAJ       Date:  1999-03-23       Impact factor: 8.262

Review 4.  Disease progression and neuroscience.

Authors:  Nick Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-04-17       Impact factor: 2.745

Review 5.  Management of schizophrenia in late life with antipsychotic medications: a qualitative review.

Authors:  Takefumi Suzuki; Gary Remington; Hiroyuki Uchida; Tarek K Rajji; Ariel Graff-Guerrero; David C Mamo
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

6.  Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia.

Authors:  Dean F Salisbury; Noriomi Kuroki; Kiyoto Kasai; Martha E Shenton; Robert W McCarley
Journal:  Arch Gen Psychiatry       Date:  2007-05

Review 7.  Longitudinal brain changes in early-onset psychosis.

Authors:  Celso Arango; Carmen Moreno; Salvador Martínez; Mara Parellada; Manuel Desco; Dolores Moreno; David Fraguas; Nitin Gogtay; Anthony James; Judith Rapoport
Journal:  Schizophr Bull       Date:  2008-01-29       Impact factor: 9.306

8.  Decreased Resting-State Interhemispheric Functional Connectivity Correlated with Neurocognitive Deficits in Drug-Naive First-Episode Adolescent-Onset Schizophrenia.

Authors:  Yi Liu; Wenbin Guo; Yan Zhang; Luxian Lv; Feihu Hu; Renrong Wu; Jingping Zhao
Journal:  Int J Neuropsychopharmacol       Date:  2018-01-01       Impact factor: 5.176

9.  Long-Term Effects of Maternal Deprivation on the Volume of Dopaminergic Nuclei and Number of Dopaminergic Neurons in Substantia Nigra and Ventral Tegmental Area in Rats.

Authors:  Slobodan Kapor; Milan Aksić; Laslo Puškaš; Marin Jukić; Joko Poleksić; Filip Milosavljević; Suncica Bjelica; Branislav Filipović
Journal:  Front Neuroanat       Date:  2020-10-23       Impact factor: 3.856

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.